Decentralising UK care: new opportunities for the enterprising
This article was originally published in Clinica
Manufacturers of medical devices and diagnostics marketing their products in the UK need to monitor closely the "enormous" changes in the delivery of care policies within the National Health Service if they wish to be among the pioneers and beneficiaries of a revised, more locally driven service. That was the message delivered by Nigel Edwards, policy director of the NHS Confederation, to the annual dinner organised by the Association of British Health-Care Industries in London at the end of November.
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.